|
US2015316568A1
|
|
Method for Screening Lyophilized Parenteral Formulations
|
|
US2015094472A1
|
|
B-lactamase inhibitor picoline salt
|
|
US2015038482A1
|
|
Isoxazole beta-lactamase inhibitors
|
|
US2015111864A1
|
|
Crystalline form of a beta-lactamase inhibitor
|
|
WO2014152763A1
|
|
Cephalosporin compositions and methods of manufacture
|
|
US2014262868A1
|
|
Ceftolozane-tazobactam pharmaceutical compositions
|
|
US2014315876A1
|
|
Beta-lactamase inhibitors
|
|
US8809314B1
|
|
Cephalosporin compound
|
|
US2014158116A1
|
|
Inhibiting trpa1 for the treatment of asthma
|
|
WO2014026073A1
|
|
Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
|
|
AU2013209387A1
|
|
Novel Antibacterial Agents for the Treatment of Gram Positive Infections
|
|
US2014024577A1
|
|
Methods for preparing purified lipopeptides
|
|
AU2013237869A1
|
|
Isoxazole beta-lactamase inhibitors
|
|
US2013289012A1
|
|
1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
|
|
US2013296555A1
|
|
Beta-lactamase inhibitors
|
|
KR20140144254A
|
|
1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
|
|
US8476425B1
|
|
Tazobactam arginine compositions
|
|
CN103945842A
|
|
Methods for treating intrapulmonary infections
|
|
AU2012205279A1
|
|
Therapeutic Compositions
|
|
CN103687589A
|
|
Cb-183,315 compositions and related methods
|
